SCOTUS denies Sandoz petition to review biosimilar Erelzi case

  -- Decision not to review Federal Circuit July 2020 ruling continues to

      prevent Sandoz launch of more affordable Erelzi treatment option for US 
      patients 
 
   -- Sandoz is disappointed US patients affected by chronic autoimmune and 
      inflammatory disease have to wait until 2029 for availability of 
      biosimilar Erelzi 
 
   -- Sandoz remains committed to pioneering access for patients and 
      contributing to more sustainable healthcare by launching biosimilar and 
      generic medicines

https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Press-Release-Novartis-US-Supreme-Court-denies-Sandoz-petition-to-review-biosimilar-Erelzi-R-eta-33279629/